Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with ...

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

This is in combination with external beam radiation therapy, to patients with first or second recurrence of the disease. As ...

Prostate cancer is the most common cancer in men worldwide. Thanks to scientific breakthroughs, there are more ways than ever to treat it — especially when it’s caught early. One ...

Telix reports early Phase 2 data showing TLX101 improves survival in recurrent brain cancer patients, with no serious side effects observed.